CoChat

Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial

Abu Dayyeh, Barham K, Maselli, Daniel B, Rapaka, Babusai, Lavin, Thomas, Noar, Mark, Hussan, Hisham, Chapman, Christopher G, Popov, Violeta, Jirapinyo, Pichamol, Acosta, Andres, Vargas, Eric J, Storm, Andrew C, Bazerbachi, Fateh, Ryou, Marvin, French, Matthew, Noria, Sabrena, Molina, Daniel, Thompson, Christopher C · 2021 · The Lancet
Cited by 109

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

BACKGROUND Intragastric balloons are anatomy-preserving, minimally invasive obesity therapies. Enhanced tolerance and durability could help broaden clinical adoption. We investigated the safety and efficacy of an adjustable intragastric balloon (aIGB) in adults with obesity. METHODS In this prospective, multicentre, open-label, randomised clinical trial done at seven US sites, adults aged 22-65 years with obesity were randomly assigned (2:1) to aIGB with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Balloon volume could be increased to facilitate weight loss or decreased for tolerability. Coprimary endpoints included mean percentage total bodyweight loss and responder rate (≥5% total bodyweight loss) at 32 weeks. We used a multiple imputed intention-to-treat population analysis. This study was registered with ClinicalTrials.gov, NCT02812160. FINDINGS Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or control (n=101 [35%]) groups. Mean total bodyweight loss at 32 weeks was 15·0% (95% CI 13·9-16·1) in the aIGB group versus 3·3% (2·0-4·6) in the control group (p<0·0001). Clinical response was observed in 171 (92%) patients in the aIGB group. Adjustments to the aIGB occurred in 145 (80%) patients for weight loss plateau or intolerance. Upward volume adjustment facilitated an additional mean 5·2% total bodyweight loss. Downward volume adjustment allowed 21 (75%) patients in the aIGB group to complete the full duration of therapy. Intolerance caused early removal of the device in 31 (17%) patients. No micronutrient deficiencies were observed in the aIGB cohort. Device-related serious adverse events were observed in seven (4%) patients, without any deaths. INTERPRETATION When aIGB was combined with lifestyle modification, significant weight loss was achieved and maintained for 6 months following removal. Balloon volume adjustability permitted individualised therapy, maximising weight loss and tolerance. FUNDING Spatz Medical.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02394-1

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 109

Metadata

Authors
Abu Dayyeh, B. K., Maselli, D. B., Rapaka, B., Lavin, T., Noar, M., Hussan, H., Chapman, C. G., Popov, V., Jirapinyo, P., Acosta, A., Vargas, E. J., Storm, A. C., Bazerbachi, F., Ryou, M., French, M., Noria, S., Molina, D., & Thompson, C. C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-11
Volume
398
Issue
10315
Pages
1965-1973
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3212659112
Cited by
109
References
15
FWCI
15.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02394-1
The paper
Abu Dayyeh, B. K., Maselli, D. B., Rapaka, B., Lavin, T., Noar, M., Hussan, H., Chapman, C. G., Popov, V., Jirapinyo, P., Acosta, A., Vargas, E. J., Storm, A. C., Bazerbachi, F., Ryou, M., French, M., Noria, S., Molina, D., & Thompson, C. C. (2021). Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)02394-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.